drugset

drugset / Trial / NCT00412880

BI 2536 Second Line Monotherapy in SCLC

NCT00412880 ↗

Phase 2 Completed 23 enrolled Boehringer Ingelheim

NaSingle-groupOpen-labelTreatment

Summary

Open label, uncontrolled Phase II trial to assess the efficacy and safety of BI 2536 in second line treatment in sensitive-relapse SCLC patients.

Timeline

Start: 2007-02-14
Primary completion: 2008-06-30
Completion: 2008-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BI 2536	Small molecule	200 mg	Intravenous

Indications